Coeptis Therapeutics withdraws warrants from Nasdaq

Coeptis Therapeutics Holdings, Inc. notified Nasdaq of the removal of its warrants from listing and registration under Section 12(b) via Form 25.

Accepted by SEC EDGAR 04/24/2026 - 05:07 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Coeptis Therapeutics Holdings, Inc. notified Nasdaq of the removal of its warrants from listing and registration under Section 12(b) via Form 25. The filing states the Exchange and the Issuer complied with rules governing voluntary withdrawal and Nasdaq certified its grounds for the Form 25 filing.

Key Figures

Commission File Number: 001-39669 Document expiry reference: March 31, 2018 Issuer address zip: 33139

3 metrics

Commission File Number 001-39669 Form 25 cover identification

Document expiry reference March 31, 2018 Expires line at document header

Issuer address zip 33139 Principal executive offices address

Key Terms

Form 25, 17 CFR 240.12d2-2, withdrawal of registration

3 terms

Form 25 regulatory

"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING"

A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.

17 CFR 240.12d2-2 regulatory

"Pursuant to 17 CFR 240.12d2-2(b) the Exchange has complied"

A U.S. Securities and Exchange Commission rule that describes the conditions and procedural steps for a security to be removed from public registration or reporting under the Securities Exchange Act of 1934. For investors, it matters because it explains when a company’s shares can stop being subject to regular disclosure and exchange listing rules — similar to knowing when a publicly tracked product will be discontinued and no longer send updates, which affects transparency and liquidity.

withdrawal of registration regulatory

"voluntary withdrawal of the class of securities from listing and registration"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Coeptis (COEP) Form 25 mean for its warrants?

It means Nasdaq has been notified to remove the company’s warrants from listing and registration. The filing states the Exchange and Issuer complied with rules for voluntary withdrawal; it does not provide trading suspension details or subsequent listing plans.

Will Coeptis (COEP) common stock be affected by this Form 25?

The Form 25 in this excerpt addresses the company’s warrants only. It does not state any change to common stock listing or registration. Any effect on other securities is not mentioned in the provided text.

Who certified the Form 25 filing for Coeptis (COEP)?

Nasdaq Stock Market LLC certified the notification and it was signed on behalf of the Exchange by Tara Petta, AVP. The filing states Nasdaq believes it meets requirements to file the Form 25 under the Exchange Act.

Does the Form 25 excerpt state a reason for the warrants' removal?

The excerpt cites compliance with rules for voluntary withdrawal under 17 CFR 240.12d2-2 but does not provide a specific business or operational reason for removing the warrants from Nasdaq listing.

Where is Coeptis Therapeutics' principal office listed in the filing?

The filing lists the Issuer’s principal executive offices at 801 S. Pointe Drive, Suite TH-1, Miami Beach, FL 33139 and provides a telephone number. This is provided as contact information in the Form 25.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-39669

Issuer:	Coeptis Therapeutics Holdings, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	801 S. Pointe Drive, Suite TH-1
	Miami Beach	FLORIDA	33139
Telephone number:					(305) 671-3341

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

warrants

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-04-24	By	Tara Petta		AVP
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.